| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2024―Feb―24 |
The epidemiology of inflammatory bowel diseases during the COVID-19 pandemic: comparison of two nationwide cohorts |
Ohad Atia, Nicklas Bryder, Adi Mendelovici, Natan Ledderman, Amir Ben-Tov, Mehdi Osooli, Anders Forss, Yiska Loewenberg Weisband, Eran Matz, Iris Dotan, Dan Turner, Ola Olén |
| 2 |
[GO] |
2024―Jan―24 |
P393 The frequency of COVID-19 infection and the impact of vaccination on the disease morbidity in Polish pediatric patients with Inflammatory Bowel Disease |
E Derda, E Szymanska, M Meglicka, A wiernicka, M Osiecki, J Kierkus |
| 3 |
[GO] |
2024―Jan―24 |
P1222 Gut microbiome differences regarding lifestyle and the history of COVID-19 infection in ulcerative colitis patients |
Z Straume, N Krumina, I Elbere, M Rozenberga, D Rudzite, J Ozolina, J Pjalkovskis, K Megnis, V Skuja, A Krumina |
| 4 |
[GO] |
2024―Jan―24 |
P1179 Long-term impact of COVID-19 on the disease course of IBD: a meta-analysis |
E S Vitus, S Mann, C Lees, T Jess, R Elmahdi |
| 5 |
[GO] |
2024―Jan―24 |
P780 Persistence of Health-related Quality of life decline in IBD patients after the COVID-19 outbreak |
C M Herrera De Guise, L F Mayorga Ayala, X Serra Ruiz, V Robles Alonso, E Céspedes Martínez, F Casellas, Z Pérez Martínez, E Oller Jimenez, N Borruel Sainz |
| 6 |
[GO] |
2024―Jan―24 |
P1097 The effect of lockdowns during the COVID-19 pandemic on the epidemiology of inflammatory bowel diseases: a comparison of two nationwide cohorts |
O Atia, N Bryder, A Mendelovici, N Ledderman, A Ben-Tov, M Osooli, A Forss, Y Loewenberg Weisband, E Matz, I Dotan, D Turner, O Olén |
| 7 |
[GO] |
2024―Jan―24 |
P898 Hesitancy on COVID-19 Vaccination Among Patients with Inflammatory Bowel Disease in South Korea: A Multicenter Survey |
S B Kang, H S Moon, Y Jung, D S Kim, H S Koo, K C Huh |
| 8 |
[GO] |
2024―Jan―24 |
P899 Inflammatory Bowel Disease Patients Show More Recognizable Digestive Symptoms of COVID-19: A Questionnaire Study |
Z Xu, M zhimin, J lujia |
| 9 |
[GO] |
2024―Jan―24 |
P395 The frequency of SARS-CoV-2 infection and the impact of vaccination on the disease morbidity in Polish pediatric patients with Inflammatory Bowel Disease treated with biologic therapies |
E Derda, E Szymanska, M Meglicka, A Wiernicka, M Osiecki, J Kierkus |
| 10 |
[GO] |
2024―Jan―24 |
P1056 T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients with inflammatory bowel disease on TNF inhibitor treatment, a prospective cohort study |
K H Bjørlykke, A S Wolf, H S Ørbo, S Bhandari, G Solum, I F Kjønstad, K P Lund, A T Tveter, J Sexton, I Jyssum, G B Kro, J Jahnsen, E A Haavardsholm, G Grødeland, S A Provan, H Kared, F Lund-Johansen, L A Munthe, S W Syversen, G L Goll, S Mjaaland, K K Jørgensen |
| 11 |
[GO] |
2024―Jan―24 |
P883 Impaired long-term quantitative cellular response to SARS-COV-2 vaccine in thiopurine-treated IBD patients |
L F Mayorga Ayala, C Herrera-deGuise, J Esperalba, X Martinez-Gomez, E Céspedes Martinez, X Serra Ruiz, V Robles, E Lastiri, Z Perez, E Oller, C Fernandez-Naval, M Martinez-Gallo, F Casellas, N Borruel |
| 12 |
[GO] |
2024―Jan―24 |
P139 A potential protective rule of Mannose Binding lectin (MBL) against SARS-COV2 infection in IBD patients |
G Albertini, L F Pisani, A Bolzoni, M L Annunziata, C Porta, L Pastorelli |
| 13 |
[GO] |
2024―Jan―24 |
P448 The role of SARS-CoV2 infection in the clinical outcomes of patients with Inflammatory Bowel Disease |
J K Yamamoto-Furusho, L Meza-Lopez |
| 14 |
[GO] |
2024―Jan―24 |
P1155 Impact of COVID19 pandemic and vaccination among IBD patients: a multinational cross sectional survey |
P Alavi Nejad, M Mokhtare, F Farsi, M Arshadzadeh, S Shetty, O Eslami, M Arefi, M H Emara, E Abdelsameea, J Rezaei, S M A Alavi, Q T Tran, R Salma, A Parsi, M H Ahmed, A Monged, A Quadri, A Jawad, A U Rehman, S H Lee, N S Behl, E Ghoneem |
| 15 |
[GO] |
2023―May―26 |
Impact of Holding Immunosuppressive Therapy in Patients with Inflammatory Bowel Disease Around mRNA COVID-19 Vaccine Administration on Humoral Immune Response and Development of COVID-19 Infection |
Kiran K Motwani, Jana G Hashash, Francis A Farraye, Michael D Kappelman, Kimberly N Weaver, Xian Zhang, Millie D Long, Raymond K Cross |
| 16 |
[GO] |
2023―Apr―05 |
Reduced serological response to COVID-19 booster vaccine is associated with reduced B cell memory in patients with Inflammatory Bowel Disease; VARIATION (VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON) |
Jayne Doherty, Neil O Morain, Roisin Stack, Miriam Tosetto, Rosanna Inzitiari, Sophie O Reilly, Lili Gu, Juliette Sheridan, Garret Cullen, Edel Mc Dermott, Maire Buckley, Gareth Horgan, Hugh Mulcahy, Margaret Walshe, Elizabeth J Ryan, Virginie Gautier, John Prostko, Edwin Frias, David Daghfal, Peter Doran, Colm O Morain, Glen A Doherty |
| 17 |
[GO] |
2023―Feb―18 |
Corrigendum to: The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study |
|
| 18 |
[GO] |
2023―Jan―30 |
P640 Serologic response and safety after third dose of the COVID-19 BNT162b2 vaccine in patients with Inflammatory Bowel Diseases |
H Edelman-Klapper, K M Rabinowitz, E Zittan, A Bar-Gil Shitrit, I Goren, I Avni-Biron, J E Ollech, L Lichtenstein, H Banai-Eran, H Yanai, Y Snir, M H Pauker, A Friedenberg, A Levy-Barda, A Segal, Y Broitman, E Maoz, B Ovadia, M Aharoni Golan, E Shachar, S Ben-Horin, M Mor, H Ben Zvi, T T Perets, R Eliakim, R Barkan, M Navon, M Gal-Tanamy, N T Freund, S Goren, D Cohen, I Dotan |
| 19 |
[GO] |
2023―Jan―30 |
P593 Impact of immunomodulating treatment modalities, active smoking and (repeated) COVID19 vaccination on S-antibody seroconversion in IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID) |
J Geldof, M Truyens, J Sabino, M Ferrante, J Lambert, H Lapeere, T Hillary, A Van Laethem, K de Vlam, P Verschueren, E Padalko, T Lobaton, S Vermeire |
| 20 |
[GO] |
2023―Jan―30 |
P817 Symptoms of COVID-19 in Patients with Immune Mediated Inflammatory Diseases |
T Schlosser, M Krasselt, L Elsing, M Hecker, B Holler, A Hoffmeister |
| 21 |
[GO] |
2023―Jan―30 |
P339 Zonulin concentration in patients with ulcerative colitis with and without COVID-19 infection |
O Knyazev, D Kulakov, A Kagramanova, I Tishaeva, T Baranova, A Poletova |
| 22 |
[GO] |
2023―Jan―30 |
OP21 COVID-19 morbidity/mortality and vaccination against SARS-CoV-2 in patients with Inflammatory Bowel Disease in Poland: Nationwide Data |
P Kucha, D Walkiewicz, P Wieszczy, J Reguła, E Zagórowicz |
| 23 |
[GO] |
2023―Jan―30 |
P747 The impact of COVID-19 on patients with Inflammatory Bowel Disease: A population-based study using artificial intelligence |
Ó Moralejo Lozano, P Beneyto Martín, M Abanades Tercero, C Muñoz Rosas, L Ruano Díaz, R Salmoral Luque, R Gómez Rodríguez |
| 24 |
[GO] |
2023―Jan―30 |
P363 Depression and anxiety in Clostridioides difficile infection compared with inflammatory bowel disease during the Covid-19 pandemic |
S Țurcan, V Platon, I Negru |
| 25 |
[GO] |
2023―Jan―30 |
P869 Prevalence of Depression and Anxiety before and during the COVID-19 Pandemic in Puerto Ricans with Inflammatory Bowel Disease |
J G Rivera Roman, P López-Marte, G Vallejo-Tagle, J Hernández-Torres, E A Torres, G Viñas-Joy |
| 26 |
[GO] |
2023―Jan―30 |
P324 Long-term impact of the COVID-19 pandemic on Inflammatory Bowel Disease healthcare utilization: A two-year nationwide update |
M Derks Eduarda Wilhelmina, L van Lierop, M te Groen, C Kuijpers, I D Nagtegaal, F Hoentjen |
| 27 |
[GO] |
2023―Jan―30 |
P144 Impact of major medication discontinuation during the first wave of COVID-19 pandemic on the risk of early relapse in patients with inflammatory bowel disease: a French observational retrospective study |
C Meunier, C Monte, H Hadjisavvas, A Rozieres, X Roblin, C Venturin, C Gay, B Flourie, G Boschetti, P Danion, N Mathieu, A L Charlois, M Faure, S Nancey |
| 28 |
[GO] |
2023―Jan―30 |
P895 Differences in ulcerative colitis patients regarding COVID-19 status |
Z Straume, N Krūmiņa, I Elbere, M Rozenberga, J Ozoliņa, A Krūmiņa, V Skuja |
| 29 |
[GO] |
2023―Jan―30 |
P755 Impaired antibody seroconversion after COVID-19 vaccination and negative impact of immunosuppressive treatment in Inflammatory Bowel Disease. Results from a multicentre, prospective study of GETECCU (VACOVEII) |
A B Julián, D Casas-Deza, R Vicente-Lidón, B Beltrán, E Domènech, A Gutiérrez-Casbas, M Mañosa, Y Zabana, E Caudevilla-Biota, P Corsino-Roche, E Sierra-Moros, L E Franco-Fobe, S Pina-Echevarría, E García-González, E Alfambra, C Gargallo-Pueyo, B Sicilia, L Arias, M J Alcala-Escriche, L Madero-Velázquez, R Ferreiro-Iglesias, A Palmero-Pérez, M Calafat, S Rubio-Iturria, I Moraleja-Yudego, Y Ber-Nieto, S García-Mateo, J P Gisbert, M Barreiro-de Acosta, S García-López |
| 30 |
[GO] |
2023―Jan―30 |
P733 Novelties of COVID-19 vaccination beyond efficacy: Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients |
T Resál, M Horváth, P Bacsur, K Szántó, M Rutka, A Bálint, A Fábián, R Bor, Z Szepes, J Fekete, P Miheller, T Molnár |
| 31 |
[GO] |
2023―Jan―30 |
P612 Lack of seroconversion following COVID-19 vaccination, but not treatment, is an independent risk factor for breakthrough SARS-CoV-2 infection in patients with inflammatory bowel disease: data from ESCAPE - an IG-IBD Study |
F S Macaluso, M Principi, F Facciotti, A Contaldo, A Todeschini, C Bezzio, S Saibeni, F Castiglione, O M Nardone, R Spagnuolo, M C Fantini, G Riguccio, F S Conforti, F A Caprioli, C Viganò, C Felice, G Fiorino, C Correale, G Bodini, M Milla, G Scardino, M Vernero, F Desideri, F Bossa, M Guerra, M Ventimiglia, M Mannino, G Rizzo, A Orlando |
| 32 |
[GO] |
2023―Jan―30 |
P827 SARS-CoV-2 breakthrough infections after COVID-19 vaccination in patients with Inflammatory Bowel Disease: A systematic review and meta-analysis |
N Van De Pol, Q Pan, L A A P Derikx, L Bakker, C J van der Woude, A C de Vries |
| 33 |
[GO] |
2023―Jan―30 |
P842 SARS-CoV-2 antibody titers analysis in immune mediated inflammatory disease patients after COVID-19 vaccination: a monocentric retrospective study |
I Delaleeuwe, J Aoun, A Hoyois, C Brasseur, S Di Romana, V Muls |
| 34 |
[GO] |
2023―Jan―30 |
P764 Effectiveness and safety of COVID-19 Vaccine among Patients with Inflammatory Bowel Disease: A medical center hospital-based study in central Taiwan |
Y H Wu, J W Chou, P J Huang, C P Wang, K S Cheng |
| 35 |
[GO] |
2023―Jan―30 |
P535 COVID-19 vaccine-induced neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 are diminished in patients with inflammatory bowel disease on anti-TNF or JAK-inhibitor therapy |
Z Liu, J Alexander, K Le, X Zhou, H Ibraheim, S Anandabaskaran, A Saifuddin, K Lin, L Mcfarlane, N Anand, L Constable, R Castro-Seoane, R Nice, C Bewshea, A D'Mello, G R Jones, S Balarajah, F Fiorentino, S Sebastian, P Irving, L Hicks, H Williams, A Kent, R Linger, M Parkes, K Kok, K V Patel, J Teare, D Altmann, A Hart, C Lees, R Boyton, J Goodhand, N Kennedy, K Pollock, T Ahmad, N Powell |
| 36 |
[GO] |
2023―Jan―30 |
OP24 Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with Inflammatory Bowel Disease after three doses of COVID-19 vaccine: a prospective multicentre cohort study |
Z Liu, K Le, X Zhou, J Alexander, S Lin, C Bewshea, N Chanchlani, R Nice, T McDonald, C Lamb, S Sebastian, K Kok, C Lees, A Hart, R Pollok, R Boyton, D Altmann, K Pollock, J Goodhand, N Kennedy, T Ahmad, N Powell |
| 37 |
[GO] |
2023―Jan―30 |
P870 What had the greatest impact on the quality of life of IBD patients on intravenous biological therapy in Montenegro during COVID-19? |
B Smolovic, M Lukic, M Djurovic, D Muhovic, S Bojovic |
| 38 |
[GO] |
2023―Jan―30 |
P651 Comparison of Adverse Events of SARS-CoV-2 Vaccination between Patients with Inflammatory Bowel Disease and Healthcare Workers |
J Kim, M Sagong, Y J Lee, K O Kim, E S Kim, E Y Kim, B I Jang |
| 39 |
[GO] |
2023―Jan―30 |
P559 SARS-CoV-2 vaccination does not increase the risk for flares in Inflammatory Bowel Disease patients |
L Rossier, F Seibold |
| 40 |
[GO] |
2023―Jan―30 |
P062 Antibody responses to SARS-CoV-2 vaccination outperform responses induced by natural infection in patients with IBD receiving immunosuppressive medications: a report from the ICARUS-IBD consortium |
E González Cueto, E Matthew, J Wellens, V Martinez Pazos, C Thompson, P Klenerman, K Cadwell, J F Colombel, J Satsangi, S Y Wong |
| 41 |
[GO] |
2023―Jan―30 |
P874 Comparison and Propensity Score of Seroconversion After Two Doses Of SARS-CoV-2 Vaccine in IBD Patients And Liver Transplant Recipients |
G Indellicati, M Rendina, A Todeschini, C Lillo, A Castellaneta, A M D'Uggento, A Di Leo, M Principi |
| 42 |
[GO] |
2023―Jan―30 |
P516 Humoral immune responses to SARS-CoV-2 vaccines in an ozanimod open-label extension study |
F Caldera, R Maddux, R Ungaro, A Kaur, E Brown, S Hu, J K Sheffield, D Silva, S Harris, B A C Cree |
| 43 |
[GO] |
2023―Jan―30 |
P432 Patient satisfaction and patient costs associated with telephone clinic appointments in Inflammatory Bowel Disease (IBD) following the pandemic |
L Matini, E A Stokes, F Parra Mujica, A Kormilitzin, R Kantschuster, A Punj Sharda, G Dunbar, K Song, L White, S P L Travis, A Walsh |
| 44 |
[GO] |
2023―Jan―30 |
P239 Incidence of Long COVID and impact of medications on the risk of developing Long COVID in a nationwide cohort of Inflammatory Bowel Disease patients |
N Khan, N Mahmud, M Patel, R Sundararajan, W Reinisch |
| 45 |
[GO] |
2022―Oct―17 |
Erratum to: Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study |
|
| 46 |
[GO] |
2022―Jun―29 |
The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study |
Aurelien Amiot, Jean-Francois Rahier, Filip Baert, Stephane Nahon, Ailsa Hart, Nikos Viazis, Livia Biancone, Eugeni Domenech, Catherine Reenears, Laurent Peyrin-Biroulet, Laurent Beaugerie, Johan Burisch |
| 47 |
[GO] |
2022―Apr―09 |
Impact of COVID-19 on Healthcare Resource Utilization among Patients with Inflammatory Bowel Disease in the USA |
Ryan C Ungaro, Bonnie Chou, Jason Mo, Lyann Ursos, Rachel Twardowski, Ninfa Candela, Jean-Frederic Colombel |
| 48 |
[GO] |
2022―Feb―16 |
Reduced serological response to COVID-19 vaccines in patients with IBD is further diminished by TNF inhibitor therapy; Early results of the VARIATION study (VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON) |
Jayne Doherty, Neil O Morain, Roisin Stack, Parker Girod, Miriam Tosetto, Rosanna Inzitiari, Juliette Sheridan, Garret Cullen, Edel Mc Dermott, Maire Buckley, Gareth Horgan, Hugh Mulcahy, Elizabeth J Ryan, David Daghfal, Peter Doran, Colm O Morain, Glen A Doherty |
| 49 |
[GO] |
2022―Jan―21 |
P114 SARS-CoV-2 infection in IBD: pandemic waves and predictors of severe or persistent COVID-19 |
C Taxonera Samso, D Olivares, I Blanco, E Velasco, S Molina, G López, O N López-García, C Alba, E Rey |
| 50 |
[GO] |
2022―Jan―21 |
P137 Lesions of Cytomegalovirus and Epstein Barr virus of the proximal gastrointestinal tract in patients with Inflammatory Bowel Disease after COVID-19 |
G Babayeva-Sadigova, U Makhmudov, F Quliyev, G Asadova, O Mirzazade, T Samadova, A Hasanova |
| 51 |
[GO] |
2022―Jan―21 |
DOP22 Clinical, biochemical and endoscopic disease activity of Inflammatory Bowel Diseases are not associated with the severity or long-term outcomes of COVID-19 - A Danish prospective population-based cohort study |
M Attauabi, J F Dahlerup, A Poulsen, M R Hansen, M K Vester-Andersen, S Eraslan, A P Prahm, N Pedersen, L Larsen, T Jess, A Neumann, K V Haderslev, A Molazahi, A B Lødrup, H Glerup, A M Oppfeldt, M D Jensen, K Theede, M Kiszka-Kanowitz, J B Seidelin, J Burisch |
| 52 |
[GO] |
2022―Jan―21 |
P637 Risks of Development of COVID-19 among Patients with Inflammatory Bowel Disease |
M Kappelman, X Zhang, J Lewis, G Melmed, C Siegel, E Cerciello, A Dobes, A Weaver, L Weisbein, M Long |
| 53 |
[GO] |
2022―Jan―21 |
P686 Outcomes of COVID-19 among patients with inflammatory bowel diseases and the influence of IBD-related medications- A Danish prospective population-based cohort study |
M Attauabi, J F Dahlerup, A Poulsen, M Rosager Hansen, M K Vester-Andersen, S Eraslan, A P Prahm, N Pedersen, L Larsen, T Jess, A Neumann, K V Haderslev, A Molazahi, A B Lødrup, H Glerup, A M Oppfeldt, M D Jensen, K Theede, M Kiszka-Kanowitz, J B Seidelin, J Burisch |
| 54 |
[GO] |
2022―Jan―21 |
DOP25 Clinical outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease |
P Wetwittayakhlang, F Albader, P Golovics, G Drügg Hahn, T Bessissow, A Bitton, W Afif, G Wild, P L Lakatos PhD |
| 55 |
[GO] |
2022―Jan―21 |
P313 Within, 6 months from COVID-19 BNT162b2 vaccine patients with Inflammatory Bowel Diseases treated with Anti-TNFα have significantly lower serologic responses |
K M Rabinowitz, M Navon, H Edelman-Klapper, E Zittan, A Bar-Gil Shitrit, I Goren, I Avni-Biron, J E Ollech, L Lichtenstein, H Banai-Eran, H Yanai, Y Snir, M H Pauker, A Friedenberg, A Levy-Barda, A Segal, Y Broitman, E Maoz, B Ovadia, M Aharoni Golan, E Shachar, S Ben-Horin, T T Perets, H Ben Zvi, R Eliakim, R Barkan, S Goren, N Krugliak, M Werbner, J Alter, M Dessau, M Gal-Tanamy, D Cohen, N T Freund, I Dotan |
| 56 |
[GO] |
2022―Jan―21 |
P413 Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b2 vaccines in the immunosuppressed (RESCUE) |
A P Tran, D Tassone, J C Nossent, N S Ding |
| 57 |
[GO] |
2022―Jan―21 |
P663 Mild COVID-19 disease and breakthrough cases among children with inflammatory bowel disease: An update from an international registry |
E Brenner, X Zhang, M Agrawal, R Ungaro, J F Colombel, M Kappelman |
| 58 |
[GO] |
2022―Jan―21 |
N08 The influence of the Covid-19 epidemic on access to medical advice for children with Inflammatory Bowel Disease (IBD), based on patients from The Children’s Memorial Health Institute, Warsaw (IPCZD) |
M Kotkowicz Szczur, M Matuszczyk, J Kierkuś |
| 59 |
[GO] |
2022―Jan―21 |
P217 Prevalence of COVID-19 in IBD patients treated with infliximab and vedolizumab in Croatian tertiary center - clinical observation of a case series |
V Domislović, M Brinar, S Čukovic-Čavka, N Turk, D Grgić, A Barišić, M Jelaković, Ž Krznarić |
| 60 |
[GO] |
2022―Jan―21 |
P529 Evolution of COVID19 serology in a real-life population of IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID) |
J Geldof, J Sabino, M Ferrante, J Lambert, H Lapeere, T Hillary, A Van Laethem, K De Vlam, P Verschueren, T Lobaton, S Vermeire |
| 61 |
[GO] |
2022―Jan―21 |
P268 IBD and Covid-19 in italy: comparisons between first and second pandemic wave |
C Bezzio, S Costa, A Armuzzi, F Furfaro, S Ardizzone, M Milla, F Bossa, A Orlando, F A Caprioli, F Castiglione, C Viganò, D G Ribaldone, F Zingone, R Monterubbianesi, N Imperatore, S Festa, M Daperno, L Scucchi, A Ferronato, L Pastorelli, P Balestrieri, C Ricci, M Cappello, C Felice, F Coppini, P Alvisi, V Gerardi, A Variola, S Mazzuoli, M V Lenti, S Alessandro, A Buda, F Micheli, V Ciardo, G Casella, A Viscido, G Bodini, G Fiorino, M Vernero, S Saibeni |
| 62 |
[GO] |
2022―Jan―21 |
DOP23 Long-term health consequences of COVID-19 in patients with Inflammatory Bowel Diseases - A Danish prospective population-based cohort study |
M Attauabi, J F Dahlerup, A Poulsen, M R Hansen, M K Vester-Andersen, S Eraslan, A P Prahm, N Pedersen, L Larsen, T Jess, A Neumann, K V Haderslev, A Molazahi, A B Lødrup, H Glerup, A M Oppfeldt, M D Jensen, K Theede, M Kiszka-Kanowitz, J B Seidelin, J Burisch |
| 63 |
[GO] |
2022―Jan―21 |
P235 The natural history of COVID-19 in vaccinated Inflammatory Bowel Disease patients |
N Viazis, A Theodoropoulou, E Zampeli, K Karmiris, M Tzouvala, G Bamias, I Koutroubakis, C Liatsos, K Koustenis, C Veretanos, E Papathanasiou, E Zacharopoulou, G Tribonias, V Kitsou, I Drygiannakis, S Michopoulos, G Mantzaris |
| 64 |
[GO] |
2022―Jan―21 |
DOP19 Myeloid and lymphoid cell abnormalities persist in the intestinal mucosa of patients who recover from COVID-19 infection |
H Meringer, M Tokuyama, M Tankelevich, G Martinez-Delgado, D Jha, A E Livanos, P Canales-Herrerias, F Cossarini, S Mehandru |
| 65 |
[GO] |
2022―Jan―21 |
P307 The effect of COVID-19 infection and vaccination in patients with Inflammatory Bowel Disease and Irritable Bowel Syndrome |
N Sciberras, A Pisani, C Vassallo, E Zahra Bianco, P Ellul |
| 66 |
[GO] |
2022―Jan―21 |
P240 Influence of Covid-19 infection in patients with inflamatory bowel disease with biological and no biological therapy |
M Herrador Paredes, M C Fernández Cano, A D Sánchez Capilla, M D M Martín Rodrírguez, M J Cabello Tapia, E Redondo Cerezo |
| 67 |
[GO] |
2022―Jan―21 |
P486 Treatment-emergent COVID-19 infections in ozanimod ulcerative colitis and multiple sclerosis clinical trials |
R Ungaro, C A Siegel, B A C Cree, K W Selmaj, H A Ahmad, A Pai, S Ather, A Henry, L Charles, A Petersen, C Y Cheng, S Afsari, J Sheffield, J Vaile, J F Colombel |
| 68 |
[GO] |
2022―Jan―21 |
P539 COVID-19 is Associated with Long-term Elevated Fecal Calprotectin Levels in Patients with Crohn’s Disease but not in Ulcerative Colitis |
A Shafrir, A A Benson, A Zinger, M Shauli Aharonov, L H Katz |
| 69 |
[GO] |
2022―Jan―21 |
P649 The impact of COVID-19 on quality of life among patients with inflammatory bowel diseases - A Danish prospective population-based cohort study |
M Attauabi, J F Dahlerup, A Poulsen, M R Hansen, M K Vester-Andersen, S Eraslan, A P Prahm, N Pedersen, L Larsen, T Jess, A Neumann, K V Haderslev, A Molazahi, A B Lødrup, H Glerup, A M Oppfeldt, M D Jensen, K Theede, M Kiszka-Kanowitz, J B Seidelin, J Burisch |
| 70 |
[GO] |
2022―Jan―21 |
P693 Willingness and hesitancy to the telemedicine in patients with inflammatory bowel disease during COVID-19 outbreak. Preliminary results of a survey in an Italian IBD Center |
F Bossa, M Guerra, S Carparelli, M Antonella, F Terracciano, A Costantino, F Caprioli, M R Valvano, G Martino, M Nardella, F Perri |
| 71 |
[GO] |
2022―Jan―21 |
P461 COVID-19 outcomes in patients receiving anti-TNF treatments: A systematic review and meta-analysis |
G Kokkotis, K Kitsou, I Xynogalas, V Spoulou, G Magiorkinis, G Poulakou, K Syrigos, G Bamias |
| 72 |
[GO] |
2022―Jan―21 |
P388 Asking teenagers and young adults with IBD; “what matters to you?”. A qualitative survey during the COVID-19 pandemic |
A King, A Speight |
| 73 |
[GO] |
2022―Jan―21 |
P124 Views of patients with Inflammatory Bowel Disease on their care during COVID-19 pandemic |
K Klimova, I Ajaz, C Padilla Suarez |
| 74 |
[GO] |
2022―Jan―21 |
P219 Impact of COVID-19 pandemic in patients with a first consultation for suspected inflammatory bowel disease |
L Ramos Lopez, A Hernández, M Carrillo-Palau, A Hernández-Camba, I Alonso-Abreu, C Reygosa, M Vela, G E Rodríguez, Y González-Mendez, C Tardillo, L Arranz, F Benítez-Zafra, M Hernández-Guerra |
| 75 |
[GO] |
2022―Jan―21 |
P631 Impact of Covid-19 pandemic on initiation of immunosuppressive treatment in immune-mediated diseases. -A nationwide, retrospective study |
M Kutschera, V Ritschl, R Berthold, T Stamm, H Kiener, H Maier, W Reinisch, B Benka, G Novacek |
| 76 |
[GO] |
2022―Jan―21 |
N16 ‘Same storm, different boat’… Exploring the impact of the COVID-19 pandemic on patients with Inflammatory Bowel Disease, with or without shielding: a qualitative study |
K Kemp, P Avery, R Bryant, A Cross, K Danter, A Kneebone, D Morris, A Walker, L Whitley, L Dibley |
| 77 |
[GO] |
2022―Jan―21 |
N13 Clinical service delivery implications of the Covid-19 pandemic on people with inflammatory bowel disease: a qualitative study |
K Kemp, P Avery, R Bryant, A Cross, K Danter, A Kneebone, D Morris, A Walker, L Whitley, L Dibley |
| 78 |
[GO] |
2022―Jan―21 |
P396 COVID-19 pandemic-related endoscopy delays did not translate to deleterious outcomes for patients with Inflammatory Bowel Disease: A retrospective cohort study |
J Chambers, M Gurpreet, M Maria, K Reena, W Aze Suzanne |
| 79 |
[GO] |
2022―Jan―21 |
P361 PREPARE-IBD: Physician Responses to disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease during the COVID-19 pandemic: A multicentre cohort analysis |
A Saifuddin, A Kent, S Mehta, L Hicks, H Gonzalez, J Segal, M Brooks, S Subramanian, N Bhala, T Conley, K Patel, C Lamb, G Walker, N Kennedy, S Sebastian |
| 80 |
[GO] |
2022―Jan―21 |
P659 No decrease in number of new Inflammatory Bowel Disease diagnoses in children in the Netherlands during the Covid-19 pandemic: a nationwide retrospective cohort study |
R Klomberg, A R Joling, M te Groen, C Kuijpers, H Escher, I Nagtegaal, L de Ridder |
| 81 |
[GO] |
2022―Jan―21 |
N20 Safety of extended blood monitoring for adult Inflammatory Bowel Disease (IBD) patients on oral azathioprine during the COVID-19 pandemic: a single-centre audit |
A Al-Hasani, L Younge, A Chana |
| 82 |
[GO] |
2022―Jan―21 |
P568 Impact of Biologics and Small Molecules for Inflammatory Bowel Disease on COVID-19 Related Hospitalization: A Systematic Review and Meta-analysis |
F Alrashed, H Alasfour, M Shehab |
| 83 |
[GO] |
2022―Jan―21 |
P444 COVID-19 risk factors, infection course and vaccination among patients with inflammatory bowel disease based on a Hungarian cohort |
K Farkas, M Matuz, D Kata, I Földesi, T Resál, P Bacsur, K Szántó, D Kolarovszki-Erdei, M Rutka, A Fábián, R Bor, Z Szepes, P Sarlós, P Miheller, A Zacháry, T Molnár |
| 84 |
[GO] |
2022―Jan―21 |
P092 Humoral and T cell responses to COVID-19 vaccination in IBD |
E Zhang, K Bond, O Nguyen, L Allen, L Kedzierski, K Kedzierka, B Christensen |
| 85 |
[GO] |
2022―Jan―21 |
P417 Seroconversion after COVID-19 Vaccination in Inflammatory Bowel Disease Patients |
M Horvath, Á A Csontos, M Sárközi, O Cseprekal, A Szijártó, P Miheller |
| 86 |
[GO] |
2022―Jan―21 |
P694 COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy |
L Ramos Lopez, M Carrillo-Palau, I Alonso-Abreu, C Reygosa, N Hernández-Buylla, C Amaral, A Hernández, F Benítez-Zafra, F Pérez-González, H Quintana-Díaz, M Hernández-Guerra |
| 87 |
[GO] |
2022―Jan―21 |
P565 COVID-19 vaccination satisfaction and hesitancy in patients with inflammatory bowel disease: “inside referral center” survey |
A Todeschini, A Contaldo, E Ierardi, A Di Leo, M Principi |
| 88 |
[GO] |
2022―Jan―21 |
DOP24 Japan prospective multicenter study for optimization of COVID-19 vaccinations based on the immune response and safety profile in Inflammatory Bowel Disease patients: Interim analyses of the J-COMBAT trial |
K Watanabe, T Hisamatsu, H Nakase, K Nagase, M Matsuura, N Aoyama, T Kobayashi, H Sakuraba, K Yokoyama, M Nishishita, M Esaki, F Hirai, M Nagahori, S Nanjo, T Omori, S Tanida, Y Yokoyama, K Moriya, A Maemoto, O Handa, N Ohmiya, S Shinzaki, S Kato, H Tanaka, T Uraoka, N Takatsu, H Suzuki, K Takahashi, J Umeno, Y Mishima, K Tsuchida, M Fujiya, S Hiraoka, S Yamamoto, M Saruta, M Nojima, A Andoh |
| 89 |
[GO] |
2022―Jan―21 |
P273 Inflammatory Bowel Disease and COVID-19 vaccine |
E Zahra Bianco, T Tabone, P Cassar, D Agius, D Zammit, A Vella Baldacchino, C Scicluna, K Gatt, M Ciantar, B Montebello, P Ellul, M Sciberras |
| 90 |
[GO] |
2022―Jan―21 |
P244 COVID-19 vaccine does not increase the likelihood of disease exacerbation in IBD: results from a population-based study |
R Lev Zion, G Focht, R Lujan, A Mendelovici, C Friss, S Greenfeld, R Kariv, A Ben-Tov, E Matz, D Nevo, Y Barak-Corren, I Dotan, D Turner |
| 91 |
[GO] |
2022―Jan―21 |
P387 Rapid Implementation of an Evidence-Based, Virtual COVID-19 Vaccine Education Clinic at the Nova Scotia Collaborative Inflammatory Bowel Disease Clinic (NSCIBD) Program |
H Komeylian, M Stewart, B Currie, K Phalen-Kelly, C G Heisler, J Jones |
| 92 |
[GO] |
2022―Jan―21 |
DOP26 COVID-19 vaccine effectiveness in Inflammatory Bowel Disease patients on tumor-necrosis factor inhibitors: Real world data from a mass-vaccination campaign |
R Lev Zion, G Focht, R Lujan, A Mendelovici, C Friss, S Greenfeld, R Kariv, A Ben-Tov, E Matz, D Nevo, Y Barak-Corren, I Dotan, D Turner |
| 93 |
[GO] |
2022―Jan―21 |
P610 Safety of COVID-19 vaccine in patients with Inflammatory Bowel Disease: preliminary data of a national study (ESCAPE-IBD) |
A Todeschini, F S Macaluso, A Contaldo, M Mannino, A Orlando, M Principi |
| 94 |
[GO] |
2022―Jan―21 |
P566 Humoral immune response to mRNA COVID-19 vaccine in Puerto Ricans with IBD does not differ between class of biologics |
P López Marte, L Ramos-Tollinchi, E Rodriguez-Martinó, R Medina-Prieto, S Ojeda, J Santana-Bagur, P Pantoja, C A Sariol, E A Torres |
| 95 |
[GO] |
2022―Jan―21 |
P695 Attitudes and predictors of COVID-19 vaccine uptake in patients with Inflammatory Bowel Disease |
E Zhang, A Gupta, F A Macrae, B Christensen |
| 96 |
[GO] |
2022―Jan―21 |
OP21 COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab |
J Alexander, N Kennedy, H Ibraheim, S Anandabaskaran, A Saifuddin, R Castro Seoane, Z Liu, R Nice, C Bewshea, A D’Mello, L Constable, G R Jones, S Balarajah, F Fiorentino, S Sebastian, P M Irving, L Hicks, H Williams, A Kent, R Linger, R King, M Parkes, K Kok, K Patel, D Altmann, R Boyton, J Goodhand, A Hart, C Lees, T Ahmad, N Powell |
| 97 |
[GO] |
2022―Jan―21 |
P600 Serologic response to COVID-19 vaccines in IBD patients: a prospective study |
M D Martin Arranz, L García Ramírez, D Montero Vega, E Martín-Arraz, M Sánchez Azofra, J Poza Cordon, J L Rueda Garcia, J Noci Belda, T Verges Martínez-Meco, P Blanco San Miguel, C Suarez Ferrer |
| 98 |
[GO] |
2022―Jan―21 |
P616 Safety of COVID-19 vaccines in patients with IBD |
N Dussias, A Carbone, L Melotti, H Privitera Hrustemovic, M Salice, E Scaioli, C Calabrese, F Rizzello, P Gionchetti |
| 99 |
[GO] |
2022―Jan―21 |
P040 Reduced serological response to COVID-19 vaccines in patients with IBD is further diminished by TNF inhibitor therapy; Early results of the VARIATION study (VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON) |
J Doherty, R Stack, N O’ Morain, P Girod, M Tosetto, R Inzitari, J Sheridan, G Cullen, M Buckley, H Mulcahy, E J Ryan, D Daghfal, P Doran, C O Morain, G Doherty |
| 100 |
[GO] |
2022―Jan―21 |
P207 COVID-19: a prevalence rate two times lower than that of the general population in French patients with Inflammatory Bowel Disease treated with intravenous biologic agents |
M Lelong, S Nancey, G Bouguen, M Allez, M Serrero, A Chupin, L Caillo, S Viennot, P Blanc, J M Reimund, D Laharie, R Olivier, P B Laurent, N Dib, A De Maissin, C Montuclard, C Trang-Poisson, G Gaillot, C Bressollette-Bodin, M Berthome, M Burel, F Vavasseur, A Bourreille, C Le Berre |
| 101 |
[GO] |
2022―Jan―21 |
P606 Use of TNF-α-antagonists and systemic steroids is associated with attenuated immunogenicity against SARS-CoV-2 in fully vaccinated patients with Inflammatory Bowel Disease |
A T Otten, A R Bourgonje, P P Horinga, H H van der Meulen, C C van Leer-Buter, G Dijkstra, M C Visschedijk |
| 102 |
[GO] |
2022―Jan―21 |
P211 Vaccination against Sars-Cov-2 in IBD patients: experience from a single tertiary referral centre |
C Bezzio, A D Guarino, I Arena, C Della Corte, M Devani, G Manes, M Schettino, E Sablich, M Vernero, S Saibeni |
| 103 |
[GO] |
2022―Jan―21 |
P720 Similar risk of infection with SARS-CoV-2 in immunocompromised and immunocompetent patients with inflammatory bowel disease and healthy controls |
B Kante, S K Vuyyuru, R Gupta, T Dwivedi, P Kumar, S Mundhra, R Golla, S Virmani, M Verma, G Makharia, V Ahuja, S Kedia |
| 104 |
[GO] |
2022―Jan―21 |
P646 Will the screening of SARS-COV-2 infection in IBD infusion centers be useful? |
N Abreu, A Oliveira, H Morna, L Jasmins |
| 105 |
[GO] |
2022―Jan―21 |
DOP20 Functional viral neutralisation responses after SARS-CoV-2 infection in Inflammatory Bowel Disease patients receiving infusion therapies: Report from the ICARUS-IBD Consortium |
J Wellens, M Edmans, U Obolski, L Marlow, S Brann, S Dunachie, D Eyre, D Helmus, E Barnes, J F Colombel, S Y Wong, P Klenerman, J O Lindsay, C P Thompson, J Satsangi |
| 106 |
[GO] |
2022―Jan―21 |
P354 Immunological response to vaccination against SARS-COV-2 infection in Inflammatory Bowel Disease patients under immunosuppressive therapy: should we prioritize an additional booster injection? |
V Macedo Silva, T Lima Capela, M Freitas, T Cúrdia Gonçalves, P Boal Carvalho, F Dias de Castro, M J Moreira, J Cotter |
| 107 |
[GO] |
2022―Jan―21 |
P150 Increased risk of ibd flare after sars-cov-2 infection. who’s the more guilty: viral infection or therapy withdrawal? |
C Bezzio, A D Guarino, G Fiorino, A Armuzzi, D G Ribaldone, F Furfaro, D Pugliese, M Vernero, A Variola, V Gerardi, L Scucchi, C Viganò, F A Caprioli, J Roselli, F Coppini, S Ardizzone, S Onali, F Zingone, M Daperno, C Cortellezzi, S Carparelli, A Soriano, G Manes, S Saibeni |
| 108 |
[GO] |
2022―Jan―21 |
P588 T cell response to SARS-CoV-2 mRNA vaccines by an interferon-gamma release immunoassay in patients with Inflammatory Bowel disease receiving anti-TNF and thiopurine treatment |
L F Mayorga Ayala, C Herrera-deGuise, J Esperalba, X Martinez-Gomez, E Céspedes Martinez, V Robles Alonso, A Jimenez, Z Perez Martinez, E Oller, A Ibarz, C Fernandez-Naval, M Martinez-Gallo, M Lopez Messeguer, F Casellas, N Borruel |
| 109 |
[GO] |
2022―Jan―21 |
P342 Trans-continental analysis of over, 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium |
S Y Wong, D Helmus, L Marlow, V Martinez Pazos, S Brann, J Wellens, S Kedia, J W Y Mak, D Bergemalm, M Argollo, C Zaltman, F Steinwurz, D Rubin, M Allez, J Halfvarson, M T Abreu, J Lindsay, U Dutta, M S Silverberg, S C Ng, V Ahuja, K Watanabe, S Vermeire, J F Colombel, J Satsangi |
| 110 |
[GO] |
2022―Jan―21 |
DOP21 Potential mechanisms linking biological therapies on SARS-CoV-2 susceptibility in Inflammatory Bowel Disease patients |
L F Pisani, S Mola, G Crespi, F Caprioli, L Pastorelli, M L Annunziata, M Manfredi, C Porta |
| 111 |
[GO] |
2022―Jan―21 |
P668 Real world use and adverse events of SARs-CoV-2 vaccination in Greek patients with Inflammatory Bowel Disease |
E Orfanoudaki, E Zacharopoulou, V Kitsou, K Karmiris, A Theodoropoulou, G J Mantzaris, M Tzouvala, S Michopoulos, E Zampeli, G Michalopoulos, P Karatzas, N Viazis, C Liatsos, G Bamias, I E Koutroubakis |
| 112 |
[GO] |
2022―Jan―21 |
OP22 Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients |
S Lin, N A Kennedy, A Saifuddin, D Muñoz Sandoval, C J Reynolds, R C Seoane, S H Kottoor, F P Pieper, K M Lin, D K Butler, N Chanchlani, R Nice, D Chee, C Bewshea, M Janjua, T J McDonald, S Sebastian, J L Alexander, L Constable, J C Lee, C D Murray, A L Hart, P M Irving, G R Jones, K B Kok, C A Lamb, C W Lees, D M Altmann, R J Boyton, J R Goodhand, N Powell, T Ahmad |
| 113 |
[GO] |
2022―Jan―21 |
DOP27 Humoral immune response after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases treated with immunosuppressive therapy - a Target to B! study |
A Volkers, L Wieske, K van Dam, M Steenhuis, E Stalman, L Kummer, Z van Kempen, J Killestein, S Tas, L Boekel, G Wolbink, B Takkenberg, P Spuls, A Bosma, B Rutgers, J Verschuuren, L van Ouwerkerk, D van der Woude, P van Paassen, M Busch, E Brusse, D Hijnen, A ten Brinke, N Verstegen, G D’Haens, M van Ham, T Kuijpers, T Rispens, M Löwenberg, F Eftimov |
| 114 |
[GO] |
2022―Jan―21 |
P605 Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases; a prospective cohort study |
K K Jørgensen, S W Syversen, I Jyssum, A T Tveter, T T Tran, J Sexton, S A Provan, S Mjaaland, D J Warren, T K Kvien, G Grødeland, L S Nissen-Meyer, P Ricanek, A Chopra, A M Andersson, G B Kro, J Jahnsen, L A Munthe, E A Haavardsholm, J T Vaage, F Lund-Johansen, G L Goll |
| 115 |
[GO] |
2022―Jan―21 |
P685 Strong Response to SARS-CoV-2 Vaccine Additional Doses among Patients with Inflammatory Bowel Diseases |
M Kappelman, K Weaver, X Zhang, K Chun, M Long |
| 116 |
[GO] |
2021―Nov―09 |
Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases - a Danish prospective population-based cohort study with individual-level data |
Mohamed Attauabi, Jens Frederik Dahlerup, Anja Poulsen, Malte Rosager Hansen, Marianne Kajbæk Verner-Andersen, Sule Eraslan, August Pilegaard Prahm, Natalia Pedersen, Lone Larsen, Tine Jess, Anders Neumann, Kent V Haderslev, Akbar Molazahi, Anders Berg Lødrup, Henning Glerup, Asser Mathiassen Oppfeldt, Michael Dam Jensen, Klaus Theede, Marianne Kiszka-Kanowitz, Jakob Benedict Seidelin, Johan Burisch |
| 117 |
[GO] |
2021―Oct―29 |
“Safety of COVID-19 vaccination in inflammatory bowel disease patients on biologic therapy” |
Isabel Garrido, Susana Lopes, Guilherme Macedo |
| 118 |
[GO] |
2021―Sep―24 |
Inflammatory Bowel Disease Clinical Activity Is Associated with COVID-19 Severity Especially in Younger Patients |
Amanda Ricciuto, Christopher A Lamb, Eric I Benchimol, Gareth J Walker, Nicholas A Kennedy, M Ellen Kuenzig, Gilaad G Kaplan, Michael D Kappelman, Ryan C Ungaro, Jean-Frederic Colombel, Erica J Brenner, Manasi Agrawal, Walter Reinisch, Anne M Griffiths, Shaji Sebastian |
| 119 |
[GO] |
2021―Sep―02 |
Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients |
Neil Chanchlani, Simeng Lin, Desmond Chee, Benjamin Hamilton, Rachel Nice, Arkir Zehra, Claire Bewshea, Bessie Cipriano, Lauranne A A P Derikx, Allan Dunlop, Louise Greathead, Rachel L Griffiths, Hajir Ibraheim, Peter Kelleher, Klaartje B Kok, Charlie W Lees, Jonathan MacDonald, Shaji Sebastian, Philip J Smith, Timothy J McDonald, Peter M Irving, Nick Powell, Nicholas A Kennedy, James R Goodhand, Tariq Ahmad |
| 120 |
[GO] |
2021―Aug―10 |
T cell response after SARS-CoV-2 vaccination in immunocompromised patients with inflammatory bowel disease |
P A Reuken, N Andreas, P C Grunert, S Glöckner, T Kamradt, A Stallmach |
| 121 |
[GO] |
2021―Jun―14 |
Elevated adherence to vaccination against SARS-CoV-2 among patients with Inflammatory Bowel Disease |
Edoardo G Giannini, Maria Giulia Demarzo, Giorgia Bodini |
| 122 |
[GO] |
2021―May―28 |
P610 Fear of COVID-19 among persons with Inflammatory Bowel Disease according to employment status, educational background and residential setting, as compared to persons with other gastrointestinal conditions |
B Z S Lo, A Mokrowiecka, A Mikocka-Walus, C N Bernstein, I A Trindade, J Burisch, M Barreiro-de Acosta, N Ferreira, R B Gearry, S R Knowles |
| 123 |
[GO] |
2021―May―28 |
P440 First results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID) |
J Geldof, M Truyens, J Sabino, M Ferrante, J Lambert, H Lapeere, T Hillary, A Van Laethem, K De Vlam, P Verschueren, T Lobaton, S Vermeire |
| 124 |
[GO] |
2021―May―28 |
DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study |
Y Zabana Abdo, I Marín-Jiménez, I Rodríguez-Lago, I Vera, M D Martín, I Guerra, J P Gisbert, F Mesonero, O Benítez, C Taxonera, Á Ponferrada-Díaz, M Piqueras, A Lucendo, B Caballol, M Mañosa, P Martínez-Montiel, M Bosca-Watts, J Gordillo, L Bujanda, N Manceñido, T Martínez-Pérez, A López, C Rodríguez, S García-López, P Vega, M Rivero, L Melcarne, M Calvo, M Iborra, M Barreiro-de Acosta, L Arias, J Barrio, J L Pérez, D Busquets, I Pérez-Martínez, M Navarro-Llavat, V Hernández, F Argüelles-Arias, E Domènech, M Esteve |
| 125 |
[GO] |
2021―May―28 |
P612 Lower incidence of COVID-19 in patients with Inflammatory Bowel Diseases treated with non-gut-selective biologic therapy: an observational multicentre study |
F Ferretti, M C Monico, A M Carvalhas Gabrielli, S Carmagnola, C Bezzio, S Saibeni, M Bosani, F Caprioli, S Mazza, V Casini, C Cortelezzi, M Parravicini, A Cassinotti, P Cosimo, A Indriolo, A Di Sabatino, M V Lenti, L Pastorelli, F Conforti, C Ricci, P Sarzi-Puttini, M Vecchi, G Maconi, S Ardizzone |
| 126 |
[GO] |
2021―May―28 |
P642 Effects of Covid-19 on employment in IBD patients |
M Sciberras, C Nascimento, T Tabone, K Karmiris, P Nikolaou, A Theodoropoulou, A Mula, I Goren, H Yanai, H Amir, G Mantzaris, T Georgiadi, K Foteinogiannopoulou, I Koutroubakis, M Allocca, G Fiorino, F Furfaro, K H Katsanos, F Fousekis, G Michalopoulos, J Torres, P Ellul |
| 127 |
[GO] |
2021―May―28 |
P145 Inflammatory Bowel Disease patients requiring surgery can be treated in referral centres regardless of the COVID-19 status of the hospital: results of a multicentric European study during the first COVID-19 outbreak (COVIBD-Surg) |
M Rottoli, G Pellino, M Tanzanu, C Baldi, A Frontali, M Carvello, C Foppa, C Kontovounisios, P Tekkis, F Colombo, J Sancho-Muriel, F Matteo, P Danelli, V Celentano, A Spinelli, Y Panis, G Sampietro, G Poggioli |
| 128 |
[GO] |
2021―May―28 |
P401 Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study |
C A Lamb, S Sebastian, A J Kent, J P Segal, H A Gonzalez, M J Brookes, S J Mehta, S Subramanian, N Bhala, L C Hicks, T E Conley, K V Patel, G J Walker, N A Kennedy |
| 129 |
[GO] |
2021―May―28 |
P186 Inflammatory Bowel Disease Care in the Covid-19 pandemic era: Experience from a Tunisian gastroenterology department |
W Dahmani, N Sahar, H Aya, E Nour, B A Wafa, B S Aida, B Ahlem, K Mehdi, J Hanene, J Ali |
| 130 |
[GO] |
2021―May―28 |
P641 Impact of lockdown period due to COVID-19 pandemic in patients with Inflammatory Bowel Disease |
S García Mateo, E Refaie, S J Martínez-Domínguez, C J Gargallo-Puyuelo, L Lario Quilez, P Carrera-Lasfuentes, M T Arroyo Villarino, M C Aso Gonzalvo, F Gomollón García |
| 131 |
[GO] |
2021―May―28 |
P541 Efficacy, efficiency and aceptability of telemedicine for inflammatory bowel disease patients follow-up care during the COVID-19 pandemic lockdown |
L Ramos Lopez, C Reygosa, M Carrillo-Palau, I Alonso-Abreu, Y González, R de la Barreda, C Amaral, A Hernández, F Benítez-Zafra, M Hernández-Guerra |
| 132 |
[GO] |
2021―May―28 |
P185 Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain |
A Hernandez Camba, L Ramos, M B Madrid Álvarez, L Pérez-Méndez, P Nos, V Hernández, I Guerra, N Jimenez, R Lorente, M Sierra-Ausín, D Ginard, P Varela, L Arranz, M J Cabello Tapia, Y Zabana, M Barreiro |
| 133 |
[GO] |
2021―May―28 |
P648 Physical and mental health during COVID-19 quarantine in adolescents with chronic immunocompromised conditions and inflammatory bowel disease |
L Lindoso, J Oba, L C A Miranda, M Deboni, M Jiro Ozaki, D C C Lima, L B Queiroz, C Astley, B Gualano, G V Polanczyk, R K Toma, C A A da Silva |
| 134 |
[GO] |
2021―May―28 |
Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU |
Y Zabana Abdo, I Marín-Jiménez, I Rodríguez-Lago, F Ramírez Esteso, S Meijilde, L Ramos, F Gomollón, F Muñoz, G Suris, J Ortiz de Zárate, J M Huguet, J Llaó, M García-Sepulcre, M Sierra, M Durà, S Estrecha, A Fuentes Coronel, E Hinojosa, L Olivan, E Iglesias, A Gutiérrez, P Varela, N Rull, P Gilabert, A Hernández-Camba, A Brotons, D Ginard, E Sesé, D Carpio, M Aceituno, J L Cabriada, Y González-Lama, L Jiménez, M Chaparro, A López-San Román, C Alba, R Plaza-Santos, M Piqueras, E Domènech, M Esteve |
| 135 |
[GO] |
2021―May―28 |
P531 SARS-CoV-2 infection in Elderly patients with Inflammatory Bowel Disease with or without immunosuppressants during the first year of the pandemic. An observational, descriptive, cohort study |
M Calafat Sard, C González-Muñoza, M Fortuny, C Roig, A Calm, A Mombiela, M Teller-Martin, F Cañete, F Bertoletti, L González-González, J Gordillo, M Mañosa, E Garcia-Planella, E Domènech |
| 136 |
[GO] |
2021―May―28 |
P625 Characteristics of SARS-CoV-2 infection in IBD patients in the second and third wave compared with the first wave and with the data of general population |
I Guerra Marina, A Algaba, S Castro, L Jiménez, D Garza, M D M Aller, A Granja, A Guardiola, M Gil, P Ruiz, F Bermejo |
| 137 |
[GO] |
2021―May―28 |
P611 Incidence, clinical presentation, and severity of SARS-CoV-2 infection in IBD patients in the second and the third wave of infection |
A Algaba Garcia, I Guerra, S Castro, L Jiménez, D Garza, M D M Aller, A Granja, A Guardiola, M Bellart, N Pizarro, F Bermejo |
| 138 |
[GO] |
2021―May―28 |
P623 The impact of SARS-CoV-2 outbreak on the treatment adherence and clinical outcome of patients with inflammatory bowel disease treated with biological agents |
G Martino, S Carparelli, A Marseglia, M R Pastore, M Placentino, M Nardella, M Guerra, O Palmieri, A Latiano, F Perri, F Ercolino, F Bossa |
| 139 |
[GO] |
2021―May―28 |
P626 SARS-CoV-2 seroprevalence in patients with Inflammatory Bowel Disease |
S García Mateo, S J Martínez-Domínguez, M C Aso Gonzalvo, C J Gargallo-Puyuelo, B Gallego Llera, M T Arroyo Villarino, V Laredo de la Torre, M M L Nocito Colon, L Lario Quilez, E Refaie, M Latre Santos, F Gomollón García |
| 140 |
[GO] |
2021―May―28 |
P387 Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic |
S Lin, C Bewshea, N Chanchlani, D Chee, R C Pollok, N A Kennedy, T Ahmad, J R Goodhand |
| 141 |
[GO] |
2021―May―28 |
P371 Using digital monitoring during the COVID pandemic to streamline outpatient appointments |
A J Walsh, L Matini, J Wilson, S Lyden, L Al-Hillawi, R Kantschuster, A Kormilitzin, T Smith, J Slater, S Payton, L White, H Woodley, O Brain, R Palmer, T Ambrose, J Satsangi, S P L Travis |
| 142 |
[GO] |
2021―May―27 |
N03 Information flow experiences during COVID-19 in IBD patients: a prospective observational study |
P Geens, E De Dycker, A Paps, T Lambrechts, J Sabino, M Ferrante, S Vermeire |
| 143 |
[GO] |
2021―May―27 |
P578 Adriatic-Balkan regional survey on COVID-19 in Inflammatory Bowel Disease patients |
V Borzan, V Orsic Fric, B Borzan |
| 144 |
[GO] |
2021―May―27 |
P637 Incidence rate and clinical outcome of severe COVID-19 in Inflammatory Bowel Disease patients in a population-based setting |
A Rezazadeh Ardabili, R H Creemers, D M A E Jonkers, M J L Romberg-Camps, M J Pierik, A A van Bodegraven |
| 145 |
[GO] |
2021―May―27 |
P636 The natural history of COVID-19 in patients with IBD: A nationwide study by the Hellenic Society for the Study of IBD |
G Bamias, G Kokkotis, D Christodoulou, V Delis, A Gatopoulou, O Giouleme, C Kalantzis, A Kapsoritakis, P Karatzas, K Karmiris, K Katsanos, P Kevrekidou, N Mathou, G Michalopoulos, S Michopoulos, I Papaconstantinou, D Polymeros, S Potamianos, G Poulopoulos, A Protopappas, K Soufleris, A Theodoropoulou, J K Triantafillidis, K Triantafyllou, G Tsiolakidou, E Tsironi, M Tzouvala, N Viazis, E Zacharopoulou, E Zampeli, G Papatheodoridis, G J Mantzaris |
| 146 |
[GO] |
2021―May―27 |
P275 Course of COVID-19 in patients with Inflammatory Bowel Diseases treated with biologics: the Israeli experience |
L Lichtenstein, B Koslowsky, I Avni-Biron, B Ovadia, O Ben-Bassat, T Naftali, U Kopylov, Y Haberman, H Banai Eran, R Eliakim, A Lahat-Zok, A Hirsch, E Zittan, N Maharshak, M Waterman, E Israeli, I Goren, J E Ollech, H Yanai, B Ungar, B Avidan, D Ben Hur, B Melamud, O Segol, Z Shalem, I Dotan, S H Odes, S Ben-Horin, Y Snir, Y Milgrom, E Broide, E Goldin, S Delgado, Y Ron, N A Cohen, E Maoz, M Zborovski, S Odeh, N Abu Freha, A Bar-Gil Shitrit |
| 147 |
[GO] |
2021―May―27 |
DOP77 Effect of Inflammatory Bowel Disease and Related Medications on COVID-19 Incidence, Disease Severity, and Outcome -The Israeli Experience |
V Richter, A Bermont, D L Cohen, E Broide, H Shirin |
| 148 |
[GO] |
2021―May―27 |
P143 Depression and anxiety symptoms among patients with early inflammatory bowel disease during and after COVID-19 lockdown |
L Sempere Robles, P Bernabeu, J Cameo, A Gutiérrez, G García, M F García, M Aguas, P Zapater, M T Ruiz-Cantero, C van-der Hofstadt |
| 149 |
[GO] |
2021―May―27 |
P385 Results of a teleconsultation campaign for Inflammatory Bowel Disease (IBD) patients to check their treatment adherence and assess their level of anxiety during the first COVID-19 lockdown |
T Paupard, C Richez, J Verlynde, O Zaharia, G Quartier, H Hudziak, L Delhoustal |
| 150 |
[GO] |
2021―May―27 |
P093 COVID-19 lockdown and mental health burden in Inflammatory Bowel Disease paediatric patients: a case-control study |
F Milo, E F Romeo, F Rea, T Grimaldi Capitello, P De Angelis, P Tabarini |
| 151 |
[GO] |
2021―May―27 |
P326 An exploratory analysis of the impact of COVID-19 on colonoscopy procedures and new biologic treatment initiation among patients with Inflammatory Bowel Disease in the United States |
R Ungaro, B Chou, J Mo, L Ursos, R Twardowski, N Candela, J F Colombel |
| 152 |
[GO] |
2021―May―27 |
DOP76 No durable impact of COVID-19 on disease activity and microbiome composition in patients with IBD |
G Funez-dePagnier, S Lima, L Duenas-Bianchi, D Lai, W Ahmed, R Battat, E Scherl, D Lukin, R Longman |
| 153 |
[GO] |
2021―May―27 |
P620 Pivoting in a pandemic: The impact of COVID-19 on the provision of care for patients with Inflammatory Bowel Disease - A retrospective study |
G Malhi, J Chambers, G Minhas, M Mikail, R Khanna, A Wilson |
| 154 |
[GO] |
2021―May―27 |
P532 Delay of maintenance infliximab increases the risk of relapse in Crohn’s disease during the COVID-19 pandemic |
H Guo, J Tang, Z Huang, B Li, Q Yang, K Chao, X Gao |
| 155 |
[GO] |
2021―May―27 |
P178 Remote monitoring as an effective management strategy in inflammatory bowel disease: the lesson from COVID-19 pandemic |
A Busacca, E Sinagra, L Guida, L Carrozza, M Melodia, M Maida, S Battaglia, C Celsa, C Cammà, M Cappello |
| 156 |
[GO] |
2021―May―27 |
P638 Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path towards the implementation of telemedicine in Spain? |
J Del Hoyo Francisco, M Millán, A Garrido-Marín, P Nos, M Barreiro-de Acosta, L Bujanda, F de la Portilla, M Aguas |
| 157 |
[GO] |
2021―May―27 |
P434 Factors associated with medical and psycosocioeconomic changes in IBD during the COVID-19 pandemic and post-pandemic period |
S Hu, X Wang, B Shen, Q Yu, J J Zheng, Y Chen |
| 158 |
[GO] |
2021―May―27 |
N10 Experience with telemedicine during the COVID-19 pandemic and preferences for future e-health in a large IBD cohort |
S Breiteneicher, T G Le Thi, E Klucker, T Schwerd, K Csollarova, L Neuhaus, S Koletzko, H Török, L Koletzko |
| 159 |
[GO] |
2021―May―27 |
P518 Compliance with Faecal calprotectin home testing as standard during COVID-19 pandemic compared to laboratory based testing pre-COVID |
D Edwards, M Ibrahim, R Cooney, R Boulton |
| 160 |
[GO] |
2021―May―27 |
P341 Perceived risks and psychosocial burden during the COVID-19 pandemic in a large cohort of pediatric and adult patients with Inflammatory Bowel Disease |
L Koletzko, E Klucker, G Le Thi, S Breiteneicher, R Rubio-Acero, L Neuhaus, R Stark, M Standl, M Hölscher, H Török, S Koletzko, T Schwerd |
| 161 |
[GO] |
2021―May―27 |
P258 Rates of admission of acute IBD flares during the COVID-19 pandemic in a tertiary healthcare setting |
K Hazel, E Glynn, K Boland, A O’Toole |
| 162 |
[GO] |
2021―May―27 |
P525 Patients’ Perception of Risks of biologic therapy During Covid-19 Pandemic in Israel Orly Lior, Ilia Sergeev, Nahum Ruhimovich, Michal Openheim, Fabiana Benjaminov, Dan Feldman, Yehuda Ringel, Timna Naftali Division of Gastroenterology and Liver Diseases, Meir Medical Center, Kfar Saba, Israel |
O Lior, I Sergeev, N Ruhimovich, M Openheim, F Benjaminov, D Feldman, Y Ringel, T Naftali |
| 163 |
[GO] |
2021―May―27 |
P490 The impact of the COVID-19 pandemic on gastroenterologists providing care to inflammatory bowel disease patients in Canada: preliminary data of a cross-sectional survey |
M Mikail, G Malhi, A Wilson, R Khanna |
| 164 |
[GO] |
2021―May―27 |
P163 The impact of the COVID-19 pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease in The Netherlands |
E Paulides, A Pasma, N S Erler, R L A van Eijk, A C de Vries, C J van der Woude |
| 165 |
[GO] |
2021―May―27 |
N06 Patient perspectives on the role of the IBD nurse and telemedicine during COVID-19 pandemic: results from a Belgian tertiary IBD unit |
G Dewitte, J Geldof, M Truyens, T Lobaton |
| 166 |
[GO] |
2021―May―27 |
P136 Management of patients with Inflammatory Bowel Disease and their outcome during the first wave of Covid-19 pandemics |
A Viola, F Giambò, M F Chiappetta, G Costantino, S Pallio, G Navarra, A Alibrandi, W Fries |
| 167 |
[GO] |
2021―May―27 |
P503 Inflammatory bowel disease video-consulting: a satisfaction survey during the second wave of Covid-19 pandemics |
A Todeschini |
| 168 |
[GO] |
2021―May―27 |
DOP90 Physician global assessment of IBD Activity is associated with COVID-19 severity in patients aged less than 50 years |
A Ricciuto, C Lamb, E I Benchimol, G Walker, N Kennedy, M E Kuenzig, G Kaplan, A M Griffiths, W Reinisch, S Sebastian |
| 169 |
[GO] |
2021―May―27 |
P362 Longitudinal antibody response to SARS-CoV-2 infection and antibody responses to COVID-19 vaccination in Inflammatory Bowel Disease patients receiving biologics |
S Y Wong, R Dixon, S Gold, M Vicky, D Helmus, K Cadwell, J F Colombel |
| 170 |
[GO] |
2021―May―27 |
P463 COVID-19 vaccination willingness and hesitancy in patients with Inflammatory Bowel Diseases (IBD): analysis of determinants in a national survey of the Italian IBD patients’ association (AMICI Onlus) |
A Costantino, D Noviello, F S Conforti, M Aloi, A Armuzzi, F Bossa, F Ficari, S Leone, F Manguso, G Mocci, A Orlando, L Pironi, S Radice, F Rizzello, A Tongiorgi, C Costantino, M Vecchi, F Caprioli |
| 171 |
[GO] |
2021―May―27 |
P657 Acceptability of a COVID-19 vaccine among cohort of Croatian IBD patients treated in tertiary IBD centre |
V Tomasic, A Bišćanin, P Ćaćić, D Kralj, Z Dorosulić, D Ogresta, D Hrabar |
| 172 |
[GO] |
2021―May―27 |
P128 Depression, anxiety and stress among Inflammatory Bowel Disease patients during COVID-19: A UK cohort study |
R Luber, A Duff, P Pavlidis, S Honap, S Meade, S Ray, S Anderson, J Mawdsley, M Samaan, P Irving |
| 173 |
[GO] |
2021―May―27 |
OP06 5-aminosalicylates are not associated with adverse outcomes in Inflammatory Bowel Disease patients with COVID-19: Analysis from an international registry |
R Ungaro, E Brenner, M Agrawal, R B Gearry, G G Kaplan, M Kissous-Hunt, S C Ng, J F Rahier, W Reinisch, F Steinwurz, X Zhang, J D Lewis, M D Kappelman, J F Colombel |
| 174 |
[GO] |
2021―May―27 |
P171 Immune-mediated diseases (IMID) and COVID-19: results from an observational retrospective multicenter study |
C Calviño Suárez, R Dos-Santos, I Baston-Rey, F J Montero, R Ferreiro-Iglesias, I Marin-Jimenez, C M Gonzalez, E Perez-Pampin, M Barreiro-de Acosta |
| 175 |
[GO] |
2021―May―27 |
P102 Outcomes of coronavirus disease 2019 among patients with inflammatory bowel diseases and the influence of IBD-related medications- A Danish prospective population-based cohort study |
M Attauabi, A Poulsen, M Kajbæk Verner-Andersen, M Rosager Hansen, N Pedersen, A Pilegaard Prahm, A Berg Lødrup, K Haderselv, L Larsen, T Jess, H Glerup, A Molazahi, A Mathiassen Oppfeldt, J F Dahlerup, C Lodberg Hvas, A Neumann, A Wase, M Dam Jensen, T Nathan, S Jensen, K Theede, M Kiszka-Kanowitz, J Benedict Seidelin, J Burisch |
| 176 |
[GO] |
2021―May―27 |
P359 Influence of the nature of immunosuppressive therapy in patients with inflammatory bowel diseases on the level of immunoglobulins G after a Coronavirus Infection |
O Knyazev, A Kagramanova, A Lishchinskaya, K Noskova, M Chernova, T Shkurko, A Veselov, D Kulakov, I Li, A Parfenov |
| 177 |
[GO] |
2021―May―27 |
P351 SARS-CoV-2 infection and seroconversion in pediatric patients on biological therapy for Crohn’s disease: single tertiary center experience |
M Sładek, M Krucka-Kawalec, E Wojtas, P Jagielski, A Stochel-Gaudyn |
| 178 |
[GO] |
2021―May―27 |
P666 Frequency and outcome of SARS-CoV2 infection in patients with inflammatory bowel disease on different biological therapy |
T Resál, K Farkas, T Molnár |
| 179 |
[GO] |
2021―May―27 |
P112 Impact of the SARS-COV2 pandemic on patients with inflammatory bowel disease - Preliminary results of a prospective, single-center study |
L Martins Figueiredo, F Correia, M A Rafael, L Lourenço, A M Oliveira, J C Branco, L Santos, A Martins |
| 180 |
[GO] |
2021―May―27 |
P457 Long-term follow-up of patients with IBD after switching from original adalimumab to adalimumab biosimilar during COVID 19 pandemic |
K Klimova, C Padilla Suarez |
| 181 |
[GO] |
2021―May―27 |
P488 The COVID19 pandemic impact on Inflammatory Bowel Disease Patients Management in a Romanian Tertiary Gastroenterology Centre |
R Costache, R Iacob, R Vadan, T Stroie, L Gheorghe, M Diculescu, C Gheorghe |
| 182 |
[GO] |
2021―Mar―13 |
SARS-CoV-2 vaccination in IBD: past lessons, current evidence and future challenges |
Judith Wellens, Jean-Frédéric Colombel, Jack J Satsangi, Serre-Yu Wong |
| 183 |
[GO] |
2020―Nov―18 |
Seroprevalence of SARS-CoV2 in IBD patients treated with biological therapy |
Roberto Berte', Stefano Mazza, Marta Rachele Stefanucci, Daniele Noviello, Stefania Costa, Clorinda Ciafardini, Erika Mileti, Marina Mapelli, Sebastiano Pasqualato, Sergio Pinto, Agnese Favale, Maurizio Vecchi, Markus F Neurath, Raja Atreya, Massimo Claudio Fantini, Federica Facciotti, Flavio Caprioli |
| 184 |
[GO] |
2020―Oct―28 |
COVID-19 in the IBD population: The need for correct nomenclature |
Ashkan Rezazadeh Ardabili, Rob H Creemers, Adriaan A van Bodegraven |
| 185 |
[GO] |
2020―Sep―28 |
Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in a patient receiving Infliximab therapy for Inflammatory Bowel Disease |
Joseph Meredith, Cher-Antonia Khedim, Paul Henderson, David C Wilson, Richard K Russell |
| 186 |
[GO] |
2020―Sep―17 |
Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force |
Iris Dotan, Remo Panaccione, Gilaad G Kaplan, Colm O’Morain, James O Lindsay, Maria T Abreu |
| 187 |
[GO] |
2020―Sep―14 |
Letter to the Editor: Care of the Patient with IBD Requiring Hospitalisation During the COVID-19 Pandemic |
Aysha H Al-Ani, Ralley E Prentice, Britt Christensen |
| 188 |
[GO] |
2020―Sep―09 |
Prevalence of COVID-19 Symptoms among Inflammatory Bowel Disease Patients Treated with Biological Agents |
Thomas E Conley, Chris Probert, Sreedhar Subramanian |
| 189 |
[GO] |
2020―Aug―24 |
Conducting Translational Gastrointestinal Research in the Era of COVID-19 |
S Nayeri, M Walshe, S Lee, M Filice, S Rho, A Jeyakumar, J Stempak, M I Smith, M S Silverberg |
| 190 |
[GO] |
2020―Aug―07 |
Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic |
Walter Reinisch, Silvio Danese, Laurent Peyrin-Biroulet, Edward V Loftus |
| 191 |
[GO] |
2020―Jun―23 |
Clinical trials (and tribulations): the immediate effects of COVID-19 on IBD clinical research activity in the United Kingdom |
Nurulamin M Noor, Ailsa L Hart, Peter M Irving, Subrata Ghosh, Miles Parkes, Tim Raine |
| 192 |
[GO] |
2020―Jun―07 |
Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD |
S Sebastian, H A Gonzalez, L Peyrin-Biroulet |
| 193 |
[GO] |
2020―May―28 |
Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFα antibodies: a case report |
Reiko Kunisaki, Jun Tsukiji, Makoto Kudo |
| 194 |
[GO] |
2020―Apr―15 |
Impact of anti-tnfα antibodies on the risk of Covid-19 and its severity in patients with inflammatory Bowel Diseases |
Antonio Tursi, Alfredo Papa |
| 195 |
[GO] |
2020―Apr―15 |
Will COVID-19 Infection be Less Severe in Ulcerative Colitis Than in Crohn’s Patients, Due to a Lower Rate of Smokers? |
Carina Peyrin-Biroulet, Ferdinando D’Amico, Laurent Peyrin-Biroulet |
| 196 |
[GO] |
2020―Mar―27 |
COVID-19 outbreak and inflammatory bowel disease management: a questionnaire survey from realistic practice |
Xiaoyin Bai, Hong Yang, Jiaming Qian |
| 197 |
[GO] |
2020―Mar―23 |
Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection? |
Giovanni Monteleone, Sandro Ardizzone |
| 198 |
[GO] |
2020―Mar―19 |
Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan experience |
Gionata Fiorino, Mariangela Allocca, Federica Furfaro, Daniela Gilardi, Alessandra Zilli, Simona Radice, Antonino Spinelli, Silvio Danese |
|
